Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07162961

Nintedanib for Improving Reproductive Outcomes in Adenomyosis

This study aims to evaluate the effectiveness and safety of nintedanib, an antifibrotic drug, in improving live birth rates for infertile women with adenomyosis who have frozen embryos. Based on promising animal data showing reduced uterine fibrosis, participants will be randomized to receive either standard progesterone therapy plus nintedanib or progesterone therapy alone for three months before undergoing a frozen embryo transfer cycle.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Aged 20-38, diagnosed with primary or secondary infertility; with at least one vitrified high-quality blastocyst (grading ≥4BB).

Diagnosed with adenomyosis within the last 3 months by MRI or transvaginal ultrasound, meeting the criteria of the Chinese Expert Consensus on Diagnosis and Treatment of Adenomyosis.

Body Mass Index (BMI) between 18-27 kg/m².

Regular menstrual cycles, no amenorrhea or severe dysfunctional uterine bleeding.

Normal ovarian reserve (AMH > 1 ng/mL or AFC ≥ 5 per ovary), not currently receiving ovarian suppression therapy.

Signed informed consent, able to understand and voluntarily participate, and willing not to participate in other clinical trials during the study period.

Exclusion criteria

Uterine or adnexal abnormalities (e.g., intrauterine adhesions, unicornuate/bicornuate/arcuate uterus, unremoved hydrosalpinx, endometrial polyp, submucosal myoma, or intramural myoma distorting the endometrial cavity).

History of GnRH agonist injection within 3 months prior to embryo transfer.

Unexplained abnormal vaginal bleeding.

Known active pelvic inflammatory disease.

Known genital malformation unsuitable for pregnancy.

Abnormal cervical cytology (TCT) results within 1 year before screening.

Severe impairment of liver or kidney function, heart disease, or hypertension.

Known history of thrombophlebitis or thromboembolic disease.

Any known clinically significant systemic disease (e.g., diabetes, tuberculosis).

Known history of recurrent miscarriage.

Chromosomal karyotype abnormality in either partner.

Either partner has a genetic disease deemed unsuitable for childbearing per the "Maternal and Infant Health Care Law".

Either partner has been exposed to teratogenic levels of radiation, toxins, or drugs.

Any condition/combined surgery/medication/other clinically significant abnormal lab finding judged by the investigator to potentially affect trial results.

Known refusal or inability to comply with the protocol requirements for any reason.

Treatment and study plan

Nintedanib

Drug

Participants will be randomly assigned to one of two groups: the Experimental Group will receive oral nintedanib (100 mg twice daily) plus progesterone therapy for three months; the Control Group will receive progesterone therapy only.

Progesterone

Drug

For control group

Primary outcomes

  1. live birth rate

    Time frame: Up to approximately 9-12 months after embryo transfer (considering gestation)

    Defined as the delivery of any live infant after 24 weeks of gestation. Calculated as: (Number of subjects with live birth / Number of subjects undergoing embryo transfer) * 100%.

Sponsors and collaborators

Lead sponsor

Sun Yat-sen University

Other

Registry information

Official study title

A Single-center, Randomized, Prospective, Controlled Clinical Study on the Efficacy of Nintedanib in Improving Reproductive Outcomes in Women With Adenomyosis

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Sep 9, 2025
Registry last updated
Sep 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.